Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting

Lung Cancer

Volumn 89, Issue 2, 2015, Pages 161-166

  Sassier, Marion ^a   Dugué, Audrey Emmanuelle ^a   Clarisse, Bénédicte ^a   Lesueur, Paul ^a   Avrillon, Virginie ^b   Bizieux Thaminy, Acya ^c   Auliac, Jean Bernard ^d   Kaluzinski, Laure ^e   Tillon, Julie ^f   Robinet, Gilles ^g   Le Caer, Hervé ^f   Monnet, Isabelle ^h   Madroszyk, Anne ⁱ   Boza, Gabriella ^f   Falchero, Lionel ^f   Fournel, Pierre ^j   Egenod, Thomas ^k   Toffart, Anne Claire ^l   Leiber, Nathalie ^a   Do, Pascal ^a   Gervais, Radj ^a   more..

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c service de réanimation   (France)

^d Centre Hospitalier Francois Quesnay   (France)

^e Centre Hospitalier Public du Cotentin   (France)

^f CENTRE HOSPITALIER   (France)

^g BREST UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j Institut de Cancérologie Lucien Neuwirth   (France)

^k LIMOGES UNIVERSITY HOSPITAL   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Bevacizumab; Non small cell lung cancer; Pemetrexed; Renal insufficiency

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PEMETREXED; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DATA BASE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; KIDNEY FAILURE; KIDNEY FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; KIDNEY FUNCTION TEST; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREVALENCE; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KIDNEY FUNCTION TESTS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937632439     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.05.005     Document Type: Article

References (30)

1. Blais N., Kassouf E. Maintenance therapies for non-small cell lung cancer. Front Oncol 2014, 4(Aug):213.
2. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(Dec (24)):2542-2550.
3. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27(March (8)):1227-1234.
4. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(Oct (9699)):1432-1440.
5. Paz-Ares L., de Marinis F., Dediu M., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind,phase 3, randomised controlled trial. Lancet Oncol 2012, 13(March (3)):247-255.
6. Paz-ares L., de Marinis F., Dediu M., et al. Paramount: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small cell lung cancer. J Clin Oncol 2013, 31(Aug (23)):2895-2905.
7. Patel J., Socinski M.A., Garon E.B., et al. A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous non-small cell lung cancer (NS-NSCLC). J Thor Oncol 2012, 7(15, Suppl 4):S336-S338.
8. Barlesi F., Scherpereel A., Rittmeyer A., et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013, 31(Aug (24)):3004-3011.
9. Rittmeyer A., Scherpereel A., Gorbunova V.A., et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced non-squamous non-small cell lung cancer on overall survival of patients on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 2013, 31. (suppl; abstr 8014).
10. Fine J., Gray J.R. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
11. R Core Team R: A language and environment for statistical computing 2013, R Foundation or Statistical Computing, Vienna, Austria, http://www.R-project.org/.
12. Launay-Vacher V., Etessami R., Janus N., et al. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 2009, 187:69-74.
13. Park J.O., Kim S.W., Ahn J.S., et al. Phase III trial of two versus four additional cycles in patients who are non-progressive after two cycles of platinum-based chemotherapy in non-small cell lung cancer. J Clin Oncol 2007, 25(33):5233-5239.
14. Gridelli C., de Marinis F., Thomas M., et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol 2014, 9(July (7)):991-997.
15. Michels J., Spano J.P., Brocheriou I., Deray G., Khayat D., Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Reo Oncol 2009, 2:53-56.
16. Vootukuru V., Liew L.P., Nally J.V. Pemetrexed induced acute renal failure, nephrogenic diabetes incipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 2009, 3:419-422.
17. Castro M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol 2003, 21:4066-4069.
18. Glezerman I.G., Pietanza M.C., Miller V., Seshan S.V. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney D 2011, 58(5):817-820.
19. Shirali A.C., Perazella M.A. Tubulointerstitial injury associated with chemotherapeutic agents. Adv Chronic Kidney Dis 2014, 21(1):56-63.
20. Perazella M.A. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012, 7(Oct (10)):1713-1721.
21. Kurata T., Iwamoto T., Kawahara Y., Okuda M. Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 2014, 29(2):148-153.
22. Burckhardt G. Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 2012, 136(Oct (1)):106-130.
23. Hayman S.R., Leung N., Grande J.P., Garovic V.D. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012, 14(Aug (4)):285-294.
24. Halimi J.M., Azizi M., Bobrie G., et al. Vascular and renal effects of anti-angiogenic therapy. Nephrol Ther 2008, 4:602-615.
25. Kitamoto Y., Tokunaga H., Miyamoto K., Tomita K. VEGF is an essential molecule for glomerular structuring. Nephrol Dial Transpl 2002, 17(Suppl 9):25-27.
26. George B.A., Zhou X.J., Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007, 49(Feb (2)):e23-e29.
27. Lomax A.J., Hill P.A., Ashley D.M. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. J Oncol Pharm Pract 2013, 19(Dec (4)):365-368.
28. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. Engl J Med 2008, 358(March (11)):1129-1136.
29. Zhao J., Li H., Wang M.J. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer. Thorac Oncol 2009, 4(Sep (9)):1185-1187.
30. Takagi Y., Toriihara A., Nakahara Y., et al. Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. PLoS One 2013, 8(3):e59700.